Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial
نویسندگان
چکیده
BACKGROUND Patient satisfaction with antipsychotic treatment is important. Limited evidence suggests that satisfaction is associated with symptom improvement and compliance. Predictors of patient satisfaction with antipsychotic medication were examined in a study of patients with a recent exacerbation of schizophrenia. METHODS Data are from a randomized, double-blind trial comparing risperidone (n = 152), quetiapine (n = 156), and placebo (n = 73). Medication Satisfaction Questionnaire (MSQ) was completed after 14 days of treatment and after 6 weeks at last study visit. RESULTS Medication satisfaction at both time points was significantly associated in multiple regression analysis with improvement on 3 Positive and Negative Syndrome Scale (PANSS) factor scores (positive symptoms p < .01; uncontrolled hostility/excitement, p < .0005; anxiety/depression, p < .04) and treatment with risperidone (p < .03); at day 14, significant association was also found with older age (p = .01). At both time points, predictor variables explained over 30% of the variance in medication satisfaction. Change in Hamilton Depression Scale, prolactin levels, sex, and reported adverse events of extrapyramidal symptoms, sedation, and movement disorders were not significant predictors of satisfaction. Lower level of medication satisfaction at day 14 was associated with earlier discontinuation in the trial at week 6 end point. A focused principal components analysis of PANSS factors and MSQ suggested that medication satisfaction relates to 3 groups of factors in descending order of magnitude: lower levels of (a) uncontrolled hostility/excitement, (b) positive symptoms, and (c) negative symptoms, disorganized thoughts, and anxiety/depression. CONCLUSION Results give further support that treatment satisfaction is positively associated with symptom improvement, particularly psychotic symptoms, and suggest that satisfaction may also be related to compliance, as those who were more satisfied remained in the trial for a longer period of time.
منابع مشابه
Evaluation of the efficacy and safety of pregabalin as an adjuvant to antipsychotics in patients with chronic schizophrenia: a six-week pilot double-blind placebo-controlled trial
Introduction and objectives: Antipsychotics or dopamine receptor antagonists are the major components of treatment but about 10-20% of patients with schizophrenia do not benefit from treatment with antidopaminergic agents, indicating other neuronal systems may be involved in this disorder (2). Dysregulation of both excitatory and inhibitory mechanisms N-Methyl-D-aspartic acid (NMDA) and γ-Amino...
متن کاملEffect of Memantine on Positive Sign in Patients with Schizophrenia and Schizoaffective Disorders: A Randomized Double Blind Placebo Controlled Trial
Background and purpose: Memantine is a medication used to treat moderate to severe Alzheimer’s disease. Memantine targeting the glutamatergic system specifically N-Methyl-D-Aspartate offer a novel approach in treatment of psychiatric disorders such as schizophrenia and schizoaffective disorder. The purpose of this study was to evaluate the efficacy and safety of memantine in combination with an...
متن کامل5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
Introduction: Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess the efficacy of ondansetron, a 5-HT3 receptor antagonist as an adjuvant agent in the treatment of chronic...
متن کاملTAILOR – tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial
BACKGROUND The aim of the TAILOR trial is to investigate the effect of closely monitored tapering/discontinuation versus maintenance therapy with antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder and with minimum 3 months' remission of psychotic symptoms. METHODS AND DESIGN Two hundred and fifty patients will be included from the psychia...
متن کاملEffects of Bromocriptine on Negative Symptoms of Schizophrenia: A Double Blind Clinical Trial
Negative symptoms are still a major obstacle in the recovery of schizophrenic patients. Many attempts to develop novel drugs affecting negative symptoms of schizophrenia have yielded insignificant results. This study evaluates the effects of bromocriptine, a dopamine agonist, on negative symptoms of schizophrenia utilizing a placebo-controlled crossover double-blind clinical trial. Methodology:...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- BMC Psychiatry
دوره 6 شماره
صفحات -
تاریخ انتشار 2006